Eisai takes up option to acquire AkaRx
This article was originally published in Scrip
Eisai is to acquire AkaRx for $255 million, exercising an option to buy the private US firm it obtained as part of the 2008 purchase of MGI Pharma.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.